hs-CRP blood test
High-sensitivity C-reactive protein. Also called: hsCRP, High-sensitivity CRP, Cardiac CRP
hs-CRP measures low levels of C-reactive protein, a protein the liver makes when there is inflammation in the body. At the low end it is used to estimate heart and blood-vessel risk; a high result usually means a recent infection or injury.
At a glance
| What it measures | C-reactive protein, an inflammation protein made by the liver, measured with an assay sensitive enough to read low, everyday levels. |
|---|---|
| Sample | Blood (serum or plasma). Neither Labcorp nor Quest lists a fasting requirement. |
| Risk tiers | Below 1.0 mg/L lower risk, 1.0-3.0 average, above 3.0 higher. Above 10 mg/L points to infection or inflammation. |
| Common reasons it reads high | Infections, injury, inflammatory disease, excess weight, oral estrogen, and a hard workout shortly before the test. |
| Peptides that move it | Lowered in trials by Semaglutide, Tirzepatide, Survodutide and Mazdutide. No study has measured it after BPC-157. |
| Lab code | LOINC 30522-7 (Labcorp 120766, Quest 10124) |
What is hs-CRP?
C-reactive protein (CRP) is an acute-phase protein: its level rises sharply when the body is fighting an infection or repairing damaged tissue, increasing up to 1,000-fold at sites of infection or inflammation.
The "high-sensitivity" test (hs-CRP) measures the same protein, but reads the low range seen in healthy people. Labcorp describes it as a test that may add to other markers used to assess the risk of heart and blood-vessel disease. A standard CRP test, coded separately (LOINC 1988-5), is used to track acute illness.
How it is made and regulated
Where it is made
CRP is made mainly by liver cells (hepatocytes), and also by smooth muscle cells, macrophages, endothelial cells, lymphocytes and fat cells. The inflammatory messenger interleukin-6 switches on the CRP gene in the liver, working through the STAT3 signaling pathway.
What controls it
How fast the liver makes CRP is the only significant determinant of its blood level: in studies with labeled CRP, its clearance was the same in healthy people and in patients with arthritis, lupus, infections and cancer. That is why the level tracks how active the inflammation is.
Sources: [4]
How it travels in the blood
Circulating CRP is a pentamer of five identical subunits. At sites of inflammation it can break apart into single subunits (monomeric CRP), which behave differently: the pentamer activates the classical complement pathway and promotes clearance of damaged cells, while the monomer draws white cells into the area.
How long it lasts
CRP has a half-life of about 19 hours, shorter than most plasma proteins, and is cleared at the same rate whatever its concentration. About 90% of labeled CRP was recovered in the urine within 7 days.
Sources: [4]
What it does
Beyond being a marker, CRP takes part in the immune response: it is involved in the complement pathway, apoptosis, phagocytosis, nitric oxide release and the production of cytokines such as interleukin-6 and tumor necrosis factor-alpha. Whether it causes heart disease is a separate question; genetic studies suggest it does not (see the optimal-range section).
Reference ranges
hs-CRP is not reported as a normal range. Both labs report it against cardiovascular risk tiers from the 2003 statement of the American Heart Association and the Centers for Disease Control and Prevention. Quest adds a band above 10 mg/L that points to infection or inflammation rather than heart risk.
Labcorp (test 120766)
| Group | Range (mg/L) |
|---|---|
| Low risk | Below 1.00 |
| Average risk | 1.00-3.00 |
| High risk | Above 3.00 |
Labcorp prints these as "Average hs-CRP level" tiers and footnotes the 2003 CDC/AHA statement (Pearson and colleagues).
Quest Diagnostics (test 10124)
| Group | Range (mg/L) |
|---|---|
| Lower relative cardiovascular risk (age over 17) | Below 1.0 |
| Average relative cardiovascular risk | 1.0-3.0 |
| Higher relative cardiovascular risk | 3.1-10.0 |
| Persistent elevation may mean infection or inflammation | Above 10.0 |
Children and teens
| Group | Range (mg/L) |
|---|---|
| Age 17 and under | Not established |
Ranges as shown for Quest's East region. For 3.1-10.0 mg/L Quest suggests retesting in 1 to 2 weeks to exclude a benign, temporary rise from infection or inflammation.
Quest does not set a range for people aged 17 and under. Quest also lists below 1.0 mg/L as "optimal", citing Jellinger and colleagues (Endocrine Practice, 2017).
Is there an "optimal" range?
Lower is linked with lower heart risk, but there is no agreed treatment target, and genetic evidence suggests CRP itself does not cause heart disease.
Below 1 mg/L is the low-risk tier
Below 1.0 mg/L
AHA/CDC 2003 tiers, as printed by Labcorp and Quest; Quest labels it "optimal"
Both labs flag below 1.0 mg/L as the lowest relative cardiovascular risk. Quest calls it optimal, citing Jellinger and colleagues (Endocrine Practice, 2017).
2 mg/L or higher is a reason to consider a statin
2.0 mg/L or higher
2019 ACC/AHA primary prevention guideline; JUPITER trial
The guideline lists hs-CRP of 2.0 mg/L or higher as a "risk-enhancing factor" when deciding on a statin. JUPITER enrolled 17,802 people with normal LDL cholesterol and hs-CRP of 2.0 mg/L or higher; rosuvastatin cut hs-CRP by 37% and the combined heart and stroke endpoint (hazard ratio 0.56).
CRP is a marker, not a target
CRP Coronary Heart Disease Genetics Collaboration (194,418 participants, 47 studies)
People with genes that raise CRP did not have more heart disease (risk ratio 1.00 per standard deviation), unlike the 1.33 seen for measured CRP. The authors concluded CRP itself is unlikely to be even a modest cause of coronary heart disease.
Sources: [6]
What raises it
| Factor | How | How much |
|---|---|---|
| Infection, injury and inflammatory diseaseCondition | Inflammatory cytokines, mainly interleukin-6, drive the liver to make more CRP. Labcorp warns that recent tissue injury, infection or inflammation should be considered when reading the result. | Up to 1,000-fold at sites of infection or inflammation; above 10 mg/L Quest flags possible infection or inflammation [1] [2] [7] |
| Excess body weight and low activityLifestyle | In 155 people tested for heart disease, hs-CRP rose with body mass index and fell with daily physical activity. | No published magnitude [11] |
| Oral estrogenMedication | Estrogen taken by mouth passes through the liver first, where CRP is made. Transdermal estradiol (a patch) did not change CRP in the same women. | More than twofold increase after 8 weeks of oral conjugated estrogens in 21 postmenopausal women [12] [1] |
| Hard exercise just before the testLifestyle | Hard exercise briefly raises CRP. The rise right after a treadmill test was small. | +0.13 mg/L from baseline to 5 minutes after peak exercise (155 people) [11] |
| Coronary artery diseaseCondition | Atherosclerosis is an inflammatory process, and people with narrowed coronary arteries tend to have higher hs-CRP. | Median 2.93 vs 1.30 mg/L with vs without 50% or more coronary narrowing [11] |
| hCG trigger in IVFPeptide | In a small IVF study, CRP rose more after an hCG trigger than after a GnRH-agonist trigger. See the peptide table below. | 96% vs 23% rise (24 women) [13] |
What lowers it
| Factor | How | How much |
|---|---|---|
| StatinsMedication | Statins lower hs-CRP as well as LDL cholesterol. In a meta-analysis of 26 randomized trials in people with heart disease, the effect was seen with both high- and lower-intensity statins. | hs-CRP -0.97 mg/L on average (26 trials); -37% with rosuvastatin in JUPITER [14] [10] |
| Regular physical activityLifestyle | Fitter, more active people have lower CRP, and exercise training lowered it, possibly independent of weight loss. | 6-35% lower with higher activity or fitness; 16% to 41% falls in training studies [15] |
| Anti-inflammatory drugs that block interleukin-1 betaMedication | Canakinumab blocks interleukin-1 beta, upstream of interleukin-6, without changing cholesterol. In CANTOS it lowered hs-CRP and heart events. | Median hs-CRP 26 to 41 percentage points lower than placebo at 48 months (50-300 mg doses) [16] |
| GLP-1-based peptidesPeptide | Weight loss and less inflammation bring hs-CRP down. See the peptide table below. | Semaglutide: -37.8% at 104 weeks in SELECT [17] |
Peptides that affect hs-CRP
How each peptide in our library has been shown to affect CRP, strongest evidence first. Many studies used a standard CRP test rather than hs-CRP; the size column says which. "No clear effect" means CRP was measured and did not change; "Unclear" means the results conflict. No study has measured CRP or ESR after BPC-157.
| Peptide | Effect on hs-CRP | Size of effect | Evidence |
|---|---|---|---|
| Human Chorionic Gonadotropin (hCG) | Raises | Standard serum CRP. Twenty-four women in IVF (prospective, non-randomized): CRP rose 96% after an hCG trigger vs 23% after a GnRH-agonist trigger (Day-OPU vs Day-hCG)An hCG trigger in IVF raises CRP, likely from ovarian stimulation rather than hCG itself. Not studied in men using hCG. [13] | Human trials |
| Dulaglutide | Lowers | Standard CRP (latex-enhanced immunoturbidimetry), not hs-CRP. Adults with type 2 diabetes on metformin randomized to add dulaglutide (n = 30) or not (n = 30) for 12 weeks: CRP 5.7 ± 1.3 to 3.2 ± 1.1 with dulaglutide vs 5.8 ± 1.1 to 5.7 ± 1.0 on metformin alone (units printed as mg/dl)CRP fell when dulaglutide was added to metformin in a small 12-week trial, alongside weight loss. Standard CRP assay; no large-trial hs-CRP data. [18] | Human trials |
| Liraglutide | Lowers | hs-CRP. Young adults with new-onset type 2 diabetes, 8 weeks: median 1.96 → 1.47 mg/L (P = 0.002), a fall also seen with metformin (1.88 → 1.44 mg/L). Placebo-controlled 14-week trial (165 people with type 2 diabetes): dose-dependent but non-significant fall, −20% at 1.9 mg (P = 0.22). Standard CRP fell 4.5 → 3 mg/L in 20 adults with obesity and psoriasis on 3 mg for 3 months (uncontrolled)CRP tends to fall on liraglutide, but the studies showing a fall had no placebo group, and in the one placebo-controlled trial the drop was not statistically significant. [19] [20] [21] | Human trials |
| Mazdutide | Lowers | hs-CRP. Phase 2 RCT, 248 Chinese adults with overweight or obesity, mazdutide 3, 4.5 or 6 mg weekly for 24 weeks: reduced with all doses, most with 6 mg (values given only in a supplementary figure)hs-CRP fell versus baseline in a placebo-controlled phase 2 trial; no numbers were published in the main paper. [22] | Human trials |
| Semaglutide | Lowers | hs-CRP: SELECT (17 604 people with cardiovascular disease and overweight/obesity, no diabetes) -37.8% at 104 weeks; SUSTAIN 3 and PIONEER 1, 2, 5 (type 2 diabetes, N = 2482) treatment ratio 0.70-0.76 vs comparators; STEP 1, 2, 3 (semaglutide 2.4 mg, 68 weeks) CRP -44%, -39% and -48% vs placeboConsistently lowers CRP in large randomized trials, partly through weight loss and partly independent of it. [17] [23] [24] | Human trials |
| Survodutide | Lowers | hs-CRP: SYNCHRONIZE-MASLD phase 3 (216 adults with obesity and at-risk MASLD), survodutide 6.0 mg weekly for 48 weeks: -46.2% vs -7.2% with placebo (p = 0.0003)Lowered hs-CRP in a phase 3 liver-fat trial. [25] | Human trials |
| Thymosin Alpha-1 | Lowers | Standard CRP. Severe acute pancreatitis meta-analysis (5 RCTs, 706 patients): lower-dose Tα1 MD -30.12 mg/L; higher dose no significant difference (P = 0.37). COVID-19 retrospective cohort (95 patients): CRP fell more at 7 days (39.99 vs 0.53 mg/L)Lowered CRP in acutely ill hospital patients (pancreatitis, COVID-19); not studied in healthy people. [26] [27] | Human trials |
| Thyrotropin-Releasing Hormone (TRH) | Lowers | Standard CRP. Small double-blind crossover pilot in cancer-related fatigue (8 completers), IV TRH vs saline: CRP decreased (reported by the study authors in a review; no values given)One 8-person pilot reported lower CRP after TRH; no values were published. Treat as a weak signal. [28] [29] | Human trials |
| Tirzepatide | Lowers | hs-CRP: meta-analysis of 7 RCTs and 1 observational study (6 in the meta-analysis), percentage change vs placebo: MD -32.9 overall; -32.9 at 15 mg, -33.9 at 10 mg, -20.3 at 5 mgLowers hs-CRP by about a third vs placebo across trials. [30] | Human trials |
| Carnosine | No clear effect | Serum CRP (assay not described as hs-CRP): 49 adults with prediabetes or well-controlled type 2 diabetes randomised to carnosine 2 g/day or placebo for 14 weeks - no difference in CRP change. In mice with lung injury, inhaled carnosine liposomes lowered circulating CRPNo CRP change in a placebo-controlled human trial; a mouse lung-injury study did show a fall. [31] [32] | Human trials |
| Eptifibatide | No clear effect | Standard serum CRP. 25 patients with non-ST-elevation ACS given eptifibatide (two 180 microg/kg boluses plus infusion) vs 25 without: CRP not lowered at 48 h, 2 weeks or 6 months. A PCI study also found no effect on CRP one month after the procedureEptifibatide did not change CRP around heart attacks or stenting. [33] [34] | Human trials |
| Erythropoietin (EPO) | No clear effect | Standard CRP. 20 hemodialysis patients: 10 on EPO for 12 months or more vs 10 not on EPO, neither on iron: no difference in CRPLong-term EPO did not change CRP in a small hemodialysis comparison. [35] | Human trials |
| Octreotide | No clear effect | Standard CRP. 12 patients with active acromegaly treated with octreotide LAR for 24 weeks: CRP unchangedSix months of octreotide LAR did not change CRP in acromegaly. [36] | Human trials |
| Vasopressin | No clear effect | CRP (assay not stated): septic shock RCT, 42 patients, vasopressin + norepinephrine vs norepinephrine alone over 48 h: no difference between groupsAdding vasopressin in septic shock did not change CRP compared with norepinephrine alone. [37] | Human trials |
| Exenatide | Unclear | hs-CRP. Randomized trial in alcohol use disorder, once-weekly exenatide (n = 40) vs placebo (n = 37) for 26 weeks: no change in any biomarker. Uncontrolled study of 45 obese adults with type 2 diabetes on twice-daily exenatide for 6 months: hs-CRP 8.66 ± 6.02 to 5.16 ± 2.85 mg/L (P<0.001)The placebo-controlled trial found no hs-CRP change; an uncontrolled diabetes study found a fall with weight loss. [38] [39] | Human trials |
| Ghrelin | Unclear | CRP (Ella immunoassay). Heavy-drinking adults given IV ghrelin (3 mcg/kg load, then 16.9 ng/kg/min) together with IV alcohol: CRP lower vs placebo in one of the two alcohol paradigms only, with no drug × time interactionA weak, alcohol-confounded signal of lower CRP in one human laboratory study. [40] | Human trials |
| Leptin | Unclear | Standard CRP (assay not named as high-sensitivity). 20 normal-weight women on a 4-day fast: physiological r-metHuLeptin raised CRP vs placebo (change 6.3 ± 2.4 vs 0.7 ± 0.3 mg/L; P = 0.04). In lean, obese and obese type 2 diabetic adults (3 days, and 4 or 16 weeks at high pharmacologic levels) CRP did not changeLeptin raised CRP only in a fasting model; in fed people, including at high doses for up to 16 weeks, CRP did not change. [41] [42] | Human trials |
| Tesamorelin | Unclear | Standard CRP. Obese adults without HIV (n = 60), 2 mg daily for 12 months: log CRP fell vs placebo (P = 0.04). HIV with abdominal fat (273 tesamorelin vs 137 placebo, 26 weeks, CRP by nephelometry): no significant change (P = 0.54)Lowered CRP modestly in one non-HIV trial but not in the larger HIV trial. [43] [44] | Human trials |
| Alpha-Melanocyte-Stimulating Hormone (α-MSH) | Lowers | Standard CRP (not hs-CRP). Aged and young rabbits given IL-1 into the brain ventricles: central alpha-MSH inhibited the plasma CRP rise; no values in the abstractIn rabbits, alpha-MSH blocked the CRP rise caused by an inflammatory signal given into the brain. No human data. [45] | Animal studies |
| Angiotensin 1-7 | Lowers | Serum CRP (assay type not stated; not described as hs-CRP). Obese type 2 diabetic mice (n = 6 per group): Ang-(1-7) lowered CRP at 10 weeks (p < 0.01); no values in the abstractLowered CRP in diabetic mice. No human data. [46] | Animal studies |
| LL-37 | Lowers | Standard CRP. Rabbits with Staphylococcus aureus infection after femur-fracture fixation: CRP lower with LL-37 than cefalexin or saline from day 1 after surgery (P = 0.039) and back to normal by day 7 (P = 0.027)Lowered the infection-driven CRP rise in rabbits. No human data. [47] | Animal studies |
| MOTS-c | Lowers | Standard CRP (particle-enhanced immunoturbidimetric assay). Type 2 diabetic Wistar rats given MOTS-c 15 mg/kg/day i.p. for 3 weeks: CRP lower than untreated diabetic rats (P = 0.0287), although CRP was not raised by diabetes (P = 0.5197)Lowered CRP in diabetic rats, where CRP was not actually elevated to begin with. No human data. [48] | Animal studies |
| TB-500 | No clear effect | Standard CRP (mouse ELISA): mice infected with a coronavirus (MHV-A59) given recombinant full-length thymosin beta-4 showed no significant CRP change. Not TB-500 itself; no human dataThe only CRP measurement is in mice given full-length thymosin beta-4, and CRP did not change. [49] | Animal studies |
What high or low results can mean
A high result
Between 1 and 3 mg/L is average risk and above 3 mg/L higher relative cardiovascular risk. Above 10 mg/L usually reflects an infection, injury or inflammatory flare rather than heart risk.
- Recent infection, injury or surgery
- Inflammatory disease such as arthritis or lupus
- Excess weight and low activity
- Oral estrogen
- Hard exercise shortly before the test
- Coronary artery disease
A low result
Below 1 mg/L is the lowest-risk tier and needs no action. It means little inflammation at the time of the test, not protection from heart disease.
- Low inflammatory burden
- Statin treatment
- Regular exercise
How the test works
| Sample | Labcorp takes serum or plasma (red-top, gel-barrier, EDTA or heparin tube), separated from the cells within one hour of collection. Quest prefers 1 mL of serum and also accepts lithium-heparin plasma. |
|---|---|
| Fasting | Neither Labcorp nor Quest lists a fasting requirement for hs-CRP. |
| Timing | Time of day does not matter: in hourly samples over 24 hours, CRP showed no daily rhythm. Avoid testing during or just after an illness, and skip hard exercise right before the draw. |
| Lab differences | Labcorp uses an immunochemiluminometric assay and Quest an immunoturbidimetric one. A standard CRP test measures the same protein but is designed for the higher levels of acute illness. Labcorp notes that serial CRP should not be used to monitor the effects of treatment. |
| Retesting | CRP varies a lot within the same person: across 26 hs-CRP studies the median within-person coefficient of variation was 0.44. One result is a snapshot; a repeat helps before acting on it. |
| Labcorp order code | 120766: C-Reactive Protein (CRP), High Sensitivity (Cardiac Risk Assessment) |
| Quest Diagnostics order code | 10124: hs-CRP |
| LOINC codes |
|
History
CRP was discovered in pneumonia patients in 1930 and spent decades as a marker of acute infection. Sensitive assays in the 1990s showed that low-grade levels predict heart attacks, which led to the cardiovascular risk tiers used today.
- 1930Tillett and Francis describe a serum reaction in pneumonia patients with a "non-protein somatic fraction" (fraction C) of the pneumococcus, the origin of the name C-reactive protein. [53]
- 1993Vigushin, Pepys and Hawkins show that CRP is cleared at the same rate in health and disease, so its level reflects how much the liver is making. [4]
- 1997In the Physicians' Health Study, men in the top quarter of CRP had about three times the risk of heart attack of those in the bottom quarter. [54]
- 2003The CDC and AHA publish a statement on inflammation markers in cardiovascular disease; labs still print its low, average and high risk tiers. [8] [2]
- 2008The JUPITER trial shows that rosuvastatin prevents heart events in people with normal LDL cholesterol and hs-CRP of 2.0 mg/L or higher. [10]
- 2011A genetic (Mendelian randomization) analysis of 194,418 people finds that CRP itself is unlikely to cause coronary heart disease. [6]
- 2017The CANTOS trial lowers heart events with canakinumab, which reduces inflammation and hs-CRP without lowering cholesterol. [16]
FAQ
What is the difference between hs-CRP and a regular CRP test?
They measure the same protein. The high-sensitivity test reads the low levels seen in healthy people and is used for heart risk; the standard test is designed for the higher levels of acute infection and inflammation. Labs code them separately (LOINC 30522-7 for hs-CRP, 1988-5 for standard CRP).
What is a good hs-CRP level?
Below 1.0 mg/L is the lower-risk tier at both Labcorp and Quest, 1.0-3.0 mg/L average and above 3.0 mg/L higher relative cardiovascular risk. Quest labels below 1.0 mg/L "optimal".
Do I need to fast for an hs-CRP test?
Neither Labcorp nor Quest lists a fasting requirement, and CRP does not follow a daily rhythm, so the time of day does not matter.
My hs-CRP was above 10 mg/L. Is my heart at risk?
Probably not from that number alone. Quest notes that values above 10 mg/L may be associated with infection and inflammation; a cold, an injury, dental work or a flare of an inflammatory condition can do it. Repeat the test after you have recovered.
Why repeat the test?
CRP swings from week to week within the same person; across 26 hs-CRP studies the median within-person variation was 0.44 (44%). Quest suggests retesting in 1 to 2 weeks when a result is 3.1-10.0 mg/L, to rule out a short-lived rise.
Does exercise affect hs-CRP?
Both ways. A hard workout causes a small, short rise (0.13 mg/L just after a treadmill test), while regular activity is linked with 6-35% lower levels, and exercise training lowered CRP by 16% to 41%.
Can hormone therapy raise hs-CRP?
Oral estrogen can. In a crossover trial in postmenopausal women, 8 weeks of oral conjugated estrogens more than doubled CRP, while a transdermal estradiol patch did not change it.
Sources: [12]
Do statins lower hs-CRP?
Yes. A meta-analysis of 26 trials found an average fall of 0.97 mg/L, and in JUPITER rosuvastatin lowered hs-CRP by 37% while also cutting heart attacks and strokes.
Does CRP cause heart disease?
Probably not. In a genetic analysis of 194,418 people, genes that raise CRP did not raise heart disease risk, so CRP looks like a marker of the inflammation behind atherosclerosis rather than a cause.
Sources: [6]
Do peptides lower hs-CRP?
GLP-1-based peptides did in trials: Semaglutide by 37.8% at 104 weeks in SELECT, with falls also reported for Tirzepatide, Survodutide and Mazdutide. Most other peptide data come from small studies or animals, often with a standard CRP test.
References
- Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol. 2018;9:754. PMID 29706967
- Labcorp. Test 120766: C-Reactive Protein (CRP), High Sensitivity (Cardiac Risk Assessment). Methodology, use, limitations, specimen requirements, reference range and LOINC map. labcorp.com/tests/120766/c-reactive-protein-crp-high-sensitivity-cardiac-risk-assessment
- Zhang D, Sun M, Samols D, et al. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem. 1996;271(16):9503-9. PMID 8621622
- Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest. 1993;91(4):1351-7. PMID 8473487
- Olson ME, Hornick MG, Stefanski A, et al. A biofunctional review of C-reactive protein (CRP) as a mediator of inflammatory and immune responses: differentiating pentameric and modified CRP isoform effects. Front Immunol. 2023;14:1264383. PMID 37781355
- Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548. PMID 21325005
- Quest Diagnostics. Test code 10124: hs-CRP. Test directory entry (East region): methodology, specimen, reference ranges and LOINC. testdirectory.questdiagnostics.com/test/test-detail/10124/hs-crp?cc=PHP
- Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511. PMID 12551878
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376-1414. PMID 30894319
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. PMID 18997196
- Mouridsen MR, Nielsen OW, Carlsen CM, et al. High-sensitivity C-reactive protein and exercise-induced changes in subjects suspected of coronary artery disease. J Inflamm Res. 2014;7:45-55. PMID 24715762
- Vongpatanasin W, Tuncel M, Wang Z, et al. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol. 2003;41(8):1358-63. PMID 12706932
- Orvieto R, Zagatsky I, Yulzari-Roll V, et al. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation. Gynecol Endocrinol. 2006;22(8):437-40. PMID 17012105
- Kandelouei T, Abbasifard M, Imani D, et al. Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators Inflamm. 2022;2022:8732360. PMID 35125965
- Plaisance EP, Grandjean PW. Physical activity and high-sensitivity C-reactive protein. Sports Med. 2006;36(5):443-58. PMID 16646631
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. PMID 28845751
- Plutzky J, Bogdański P, Colhoun HM, et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation. 2026;154(11):976-991. PMID 42610271
- Xie D, Li Y, Xu M, et al. Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):200. PMID 36199064
- Zhang WQ, Tian Y, Chen XM, et al. Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes. Diabetol Metab Syndr. 2018;10:91. PMID 30564288
- Courrèges JP, Vilsbøll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med. 2008;25(9):1129-31. PMID 19183322
- Nicolau J, Nadal A, Sanchís P, et al. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023;161(7):293-296. PMID 37474395
- Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289. PMID 38092790
- Mosenzon O, Capehorn MS, De Remigis A, et al. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol. 2022;21(1):172. PMID 36056351
- Verma S, Bhatta M, Davies M, et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. EClinicalMedicine. 2023;55:101737. PMID 36467859
- Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026;32(8):2948-2958. PMID 42252333
- Tian Y, Yao J, Ma Y, et al. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. Front Immunol. 2025;16:1571456. PMID 40599771
- Wang T, Lin Q, Xie Y, et al. [Thymosin alpha 1 for the adjuvant treatment of coronavirus disease 2019: a retrospective cohort study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022;34(5):497-501. PMID 35728851
- Kamath J. Cancer-related fatigue, inflammation and thyrotropin-releasing hormone. Curr Aging Sci. 2012;5(3):195-202. PMID 23387883
- Kamath J, Feinn R, Winokur A. Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study. Support Care Cancer. 2012;20(8):1745-53. PMID 21947558
- Masson W, Lobo M, Nogueira JP, et al. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2026;27(1):5-15. PMID 41032183
- Saadati S, de Courten M, Deceneux C, et al. Carnosine Supplementation Has No Effect on Inflammatory Markers in Adults with Prediabetes and Type 2 Diabetes: A Randomised Controlled Trial. Nutrients. 2024;16(22). PMID 39599686
- Fang C, Xie L, Xie D, et al. Therapeutic Effects of Intratracheally Nebulized Carnosine-Loaded Liposomes on Lipopolysaccharide-Induced Acute Lung Injury. Pharmaceutics. 2026;18(9). PMID 42797265
- Mazaev AA, Naimushin YA, Masenko VP, et al. Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. J Thromb Thrombolysis. 2009;27(2):146-53. PMID 18163196
- Finkelstein A, Izraelov S, Roth A, et al. Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty. Int J Cardiovasc Intervent. 2004;6(3-4):107-9. PMID 16146902
- Pawlak K, Pawlak D, Mysliwiec M. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients. Am J Nephrol. 2007;27(3):221-5. PMID 17384500
- Potter BJ, Beauregard C, Serri O. Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR. Pituitary. 2008;11(1):49-53. PMID 17917813
- Barzegar E, Nouri M, Mousavi S, et al. Vasopressin in Septic Shock; Assessment of Sepsis Biomarkers: A Randomized, Controlled Trial. Indian J Crit Care Med. 2017;21(9):578-584. PMID 28970657
- Hviid MEB, Christoffersen LAN, Klausen MK, et al. Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial. Alcohol Clin Exp Res (Hoboken). 2025;49(8):1659-1666. PMID 40630018
- Köseoğlu D, Koparal SS, Özdemir Başer Ö, et al. Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study. Turk J Med Sci. 2021;51(1):167-174. PMID 32892547
- Farokhnia M, Portelli J, Lee MR, et al. Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies. Brain Res. 2020;1740:146851. PMID 32339499
- Canavan B, Salem RO, Schurgin S, et al. Effects of physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation during caloric deprivation. J Clin Endocrinol Metab. 2005;90(10):5779-85. PMID 16076944
- Chan JL, Bullen J, Stoyneva V, et al. Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab. 2005;90(3):1618-24. PMID 15613407
- Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-79. PMID 23015655
- Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-8. PMID 21516030
- Dao TK, Bell RC, Feng J, et al. C-reactive protein, leukocytes, and fever after central IL 1 and alpha-MSH in aged rabbits. Am J Physiol. 1988;254(3 Pt 2):R401-9. PMID 2831740
- Chen Q, Sun M, Wang H, et al. The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice. Metabolites. 2026;16(5). PMID 42188044
- Yan CY, Liu YZ, Xu ZH, et al. Comparison of Antibacterial Effect of Cationic Peptide LL-37 and Cefalexin on Clinical Staphylococcus aureus-induced Infection after Femur Fracture Fixation. Orthop Surg. 2020;12(4):1313-1318. PMID 32725811
- Mills AR, de Souza A, Pham T, et al. Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model. Exp Physiol. 2026;111(8):3742-3752. PMID 42321010
- Yu R, Mao Y, Li K, et al. Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection. Mediators Inflamm. 2021;2021:9979032. PMID 33967626
- LOINC 30522-7: C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/30522-7
- Meier-Ewert HK, Ridker PM, Rifai N, et al. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem. 2001;47(3):426-30. PMID 11238292
- Gough A, Sitch A, Ferris E, et al. Within-subject variation of C-reactive protein and high-sensitivity C-reactive protein: A systematic review and meta-analysis. PLoS One. 2024;19(11):e0304961. PMID 39485740
- Tillett WS, Francis T. SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS. J Exp Med. 1930;52(4):561-71. PMID 19869788
- Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-9. PMID 9077376
- PubMed search, October 29, 2026: ("BPC 157" OR "BPC-157" OR BPC157 OR pentadecapeptide) AND ("C-reactive" OR CRP OR sedimentation OR ESR). One result (PMID 12526704), an unrelated chemistry paper in which "ESR" means electron spin resonance; no study measured CRP or the erythrocyte sedimentation rate after BPC-157. pubmed.ncbi.nlm.nih.gov/?term=%28%22BPC%20157%22%20OR%20%22BPC-157%22%20OR%20BPC157%20OR%20pentadecapeptide%29%20AND%20%28%22C-reactive%22%20OR%20CRP%20OR%20sedimentation%20OR%20ESR%29
Educational information, not medical advice. Lab ranges and test codes were checked on October 29, 2026. Always use the range printed on your own report, and talk to a clinician about your results.